HNF4A and breast carcinoma: For example, CWP232228, the Wnt/beta-catenin inhibitor which blocks β-catenin binding to TCF in the nucleus, inhibits proliferation and activity of BCSCs (Jang et al., 2015b) and treatment with CWP232228 after tail vein injection of 4T1 mammary carcinoma cells decreased metastatic burden and increased overall survival in pre-clinical studies (Jang et al., 2015b).